在托马斯·弗里德曼（Thomas L. Friedman）的经典著作《世界是平的》中，他描绘了一个因技术进步、信息流通与全球协作而被“拉平”的世界。
在这个秩序下，产业不再局限于单一国家或地区的封闭链条，而是演变为一张纵横交错的全球分工网络——医药产业正是这一趋势的生动写照。
正如弗里德曼所言，“价值链被切割成片，每个地方做自己最擅长的事”，医药产业以空前的精细化分工，重构创新的地理版图。分散在全球的科技、资源与经验已经融合为高度协作的产业创新生态。
不久前，在英国伦敦举行的“Growth and Innovation Summit 2025”上，这一理念再次得到印证。大会由LifeSci Capital LLC与Sofinnova Partners联合主办，汇聚了欧洲及全球生命科学领域最具影响力的投资人与基金负责人。
药明康德联席首席执行官杨青博士受邀出席并参与主题讨论。他分享了全球创新生态的最新趋势，并以三个简洁而有力的故事，生动诠释了药明康德如何助力国际合作落地、支持初创企业成功融资、推动技术成果实现跨越式发展。
每一个故事背后，都是全球化分工赋能创新的真实回响，而药明康德正站在那个让科学走得更快、让梦想落得更稳的支点之上。
信任的基石——用高质量赢得国际交易的认可
数年前，一家小型生物科技公司的创新项目经过漫长的探索后，终于取得了里程碑式的突破，走到了决定命运的价值拐点。带着这份来之不易的成果，他们开始向世界伸出合作的橄榄枝，希望推动这项成果，迈向更广阔的天地。
很快，一次潜在的交易机会来临。然而，在全球交易的审核中，信任并非一纸合约便可轻易建立。买方对这家新锐公司的研发服务伙伴并不熟悉，疑虑如同薄雾笼罩在谈判桌上。为了验证核心技术的真实性与可重复性，他们提出一个关键要求：将一项核心研究，放入药明康德的平台体系中进行复现。
药明康德的高标准、高一致性的质量体系已为业界熟知和信任，于是，这项研究被置于药明康德严谨而透明的质量体系之下，最终复现的结果帮助这家小型生物科技公司赢得了买方的认可。
“我们因此成为了验证可靠性的关键一环，最终助力了交易的成功。”杨青博士说道。
这不是偶然，而是必然。
作为一个能够赋能新药研发生产全流程的CRDMO平台，药明康德始终遵循“质量源于设计（Quality by Design）”的理念，从源头到过程中的每一个环节，都恪守高标准质量，经得起随时随地的检验。
仅2024年，药明康德接受的全球客户、监管机构和独立第三方的质量审计就达到802次，约等于每个工作日都要接受3.2次审计，均100%符合质量审计要求。
正是25年来始终如一的高标准与一致性，让药明康德不仅是研发的助推者，更成为全球创新链条中值得托付的信任支点。
与时间赛跑——跨时区协作抢出IPO前的关键窗口
在生物医药的世界里，时间从不是简单的刻度，而是决定命运的砝码。一场会议，一页报告，一次亮相，都可能撬动数亿美元的融资或改变一家公司的未来轨迹。
2022年圣诞节前夕，美国街头洋溢着节日的灯火。一位正处于Pre-IPO关键阶段的生物科技公司CEO紧急致电药明康德，希望能在即将召开的摩根大通医疗健康年会（JPM）前拿到相关报告，抵达价值里程碑。机遇不等人，有些窗口稍纵即逝。
充分了解客户的诉求后，药明康德的全球化CRDMO网络迅速启动，开启跨越时区的高效协作。
JPM的举办时间是1月中旬，而彼时美国已临近圣诞假期，时间非常紧迫。接到需求的苏州基地迅速响应，即刻重新排定项目计划，调配人手和资源，提升项目的优先级。
终于，在JPM大会召开前，那份满载着期待的高品质报告，准时送达到了客户手中。
“我们为客户赢得了关键的信任票，促成了最终的交易，客户收获了圆满的结局。”杨青博士说。
这背后，是药明康德多年积淀的全球化协同的实力，是对“不可能”说不的决心，更是CRDMO平台对“速度与质量并行”的极致兑现。
那一份报告，不只是项目成果的集合，更是一张通往未来的入场券——它证明了，在创新的赛道上，一个可靠的合作伙伴，会为你全力以赴、争分夺秒。
从分子到市场——端到端赋能撬动超十亿美元授权合作
随着科学技术的飞速跃迁，那些曾被视为“不可成药”的靶点，正在逐步突破。新型药物分子如靶向蛋白降解剂、多肽、寡核苷酸等蓬勃涌现，不断刷新着疾病治愈的边界。然而，这些分子结构复杂、合成难度高，研发之路挑战重重。
创新不再仅限于科学构想，更考验着将构想变为现实的能力。真正具备“端到端”一体化服务能力的CRDMO平台，价值愈发凸显，成为推动突破性疗法从实验室走向临床的关键。
“我们的客户始终跟随科学或技术领域中的前沿趋势，开拓创新，但在此过程中也会遇到一些挑战。这正是CRDMO平台的速度与质量能够提供价值的地方。”杨青博士说道。
一款针对肥胖等代谢性疾病的肽类三靶点创新药物，展现出卓越的疗效潜力，但其高度复杂的化学结构，使得项目整体极具挑战性。
这样具有开拓性与高难度的早期研发项目，在药明康德“一体化、端到端”的全流程平台上有很多。往往从项目最初，药明康德就开始深度参与，一路“跟随客户”“跟随分子”，陪伴项目抵达一个又一个里程碑。
在药明康德的支持下，这个肽类三靶点创新药物从原料药的合成，到制剂工艺的打磨；从分析方法的建立，到首批临床样品的制备——每一步，都稳扎稳打。此后，关键的CMC数据出炉，顺利通过IND申报。当早期临床试验结果令人振奋的消息传来，那一刻，是产业对这个药物信心的建立。
很快，这一里程碑式的进展迅速吸引了全球大型医药企业的关注。最终，该项目成功实现全球权益授权，达成总金额超10亿美元的合作协议。
“合作的成果不止于交易。”杨青博士指出，“随着项目的持续推进，客户对我们的信任也在加深。更重要的是，这款新药离患者又近了一步。”
站在赋能产业创新的支点
站在赋能产业创新的支点之上，药明康德正以质量筑基、以速度为先、以“一体化、端到端”的平台能力护航每一次突破。
“CRDMO模式的价值，从来不止于促成一笔笔授权交易。”杨青博士强调，“更深远的意义在于，我们正在加速那些原本遥不可及的复杂疗法早日问世，让它们更快抵达患者手中，帮助客户真正实现产业创新的价值。”
当创新的边界不断拓展，药明康德作为全球化CRDMO平台，成为了“平坦世界”中的关键节点。
它不仅是服务提供者，更是一座桥梁——通过端到端、兼具质量与速度的一体化平台，将小型生物科技公司的科学灵感、大型药企的战略布局、投资机构的信任背书以及监管标准的严格要求无缝衔接。一个个原本孤立的科研构想，得以跨越资源、能力与地域的鸿沟，加速走向患者身边。
这种桥梁的价值，在全球创新合作火热的当下，将愈发鲜活。
Inside Three Stories of CRDMO Enabling Global Collaboration
In his classic book The World Is Flat, Thomas L. Friedman depicts a world “flattened” by technological advances, information flow, and global collaboration.
In this new order, industries are no longer confined to closed loops within a single country or region. Instead, they evolve into a complex global network of specialized capabilities—and the pharmaceutical industry exemplifies this trend.
The pharmaceutical industry, with its unprecedented specialization, is reshaping the landscape of innovation. Scientific talent, resources, and experience dispersed across the globe now converge into a highly collaborative ecosystem for innovation.
This vision was vividly reflected at the Growth and Innovation Summit 2025 in London, jointly hosted by LifeSci Capital LLC and Sofinnova Partners. The event brought together leading investors and fund managers from Europe and beyond.
WuXi AppTec Co-CEO Dr. Steve Yang was invited to speak on the summit panel. He shared the latest trends in the global innovation ecosystem and illustrated through three compelling stories how WuXi AppTec enables global collaboration, helps startups secure financing, and accelerates the translation of scientific breakthroughs into real-world impact.
Each story reflects how globalized specialization can meaningfully accelerate innovation, with WuXi AppTec standing as the fulcrum that helps science move faster and ideas land more securely.
The Foundation of Trust: Winning Global Recognition through Quality
Several years ago, a small biotech company reached a critical milestone after long-term efforts on an innovative project. This marked a decisive value inflection point for the company.
Eager to expand the project globally, the company sought potential partners. A transaction opportunity soon emerged. Yet in global deals, trust cannot be established merely through contracts. The buyer was unfamiliar with the biotech company’s service partner, and doubts hovered over the negotiation table.
To verify the reproducibility of a core study, the buyer requested that the research be repeated within WuXi AppTec’s platform.
Well-known for its rigorous, high-consistency quality system, WuXi AppTec took the study while adhering to “Quality by Design”. The results helped the biotech company secure the buyer’s trust and advance the transaction.
"We became a critical part of verifying reliability, ultimately helping the deal succeed," Dr. Yang said.
This outcome was no accident—it was the result of a platform designed to enable the entire drug R&D and manufacturing process. At WuXi AppTec, every step from concept to execution adheres to the highest quality standards. In 2024 alone, WuXi AppTec underwent 802 global audits by clients, regulators, and independent third parties—equivalent to 3.2 audits every working day, all meeting full compliance.
Racing Against Time: Cross-Time-Zone Collaboration for a Pre-IPO Window
In the pharmaceutical world, time is never a simple metric—it can determine a company’s fate. One meeting, one report, one presentation can influence hundreds of millions in financing or alter a company’s trajectory.
Before Christmas Eve 2022, as festive lights lit the streets of the United States, a biotech CEO in a critical pre-IPO phase urgently contacted WuXi AppTec. The company needed a high-quality report ahead of the upcoming JPM Healthcare Conference—a key milestone for their valuation.
Understanding the urgency, WuXi AppTec’s global CRDMO network immediately mobilized. Teams across time zones collaborated seamlessly.
The Suzhou site in China quickly reprioritized resources, adjusted schedules, and ensured that the report—packed with essential data—was delivered before the JPM conference.
"We helped our client earn a critical vote of confidence, enabling the final deal and a successful outcome," Dr. Yang said.
The report was more than a project deliverable—it was a ticket to the future. It proved that a reliable partner could accelerate progress, minute by minute, on the innovation track.
From Molecule to Market: End-to-End Support Drives Over $1 Billion in Global Licensing
As science rapidly advances, targets once considered “undruggable” are now achievable. Emerging drug modalities—protein degraders, peptides, oligonucleotides—are pushing the boundaries of disease treatment. Yet these molecules are complex, challenging to synthesize, and require meticulous R&D.
"Our customers pursue cutting-edge scientific trends, but they face challenges along the way. That’s where the speed and quality of a CRDMO platform create real value," Dr. Yang said.
One pioneering project, a peptide triple agonist for metabolic diseases, demonstrated significant potential. Its complex chemistry posed big challenges.
On WuXi AppTec’s fully integrated, end-to-end platform, many of these pioneering, high-complexity early-stage projects come to life. From day one, the team dives deep—“follow-the-customer” and “follow-the-molecule”—walking alongside each project, milestone by milestone, ensuring every step is carefully guided toward success.
With WuXi AppTec’s support, this innovative therapy advanced steadily from the synthesis of the active pharmaceutical ingredient to formulation development; from establishing analytical methods to producing the first clinical batches. Every step was carefully executed. Critical CMC data were then generated, enabling a smooth IND submission. When early clinical results showed promising outcomes, it marked a pivotal moment—building industry confidence in the molecule.
This milestone quickly drew the attention of major global pharmaceutical companies. Ultimately, the project secured a worldwide licensing agreement, with total deal value exceeding $1 billion.
"The results go beyond the transaction," Dr. Yang noted. "As the project progresses, our customers’ trust deepens—and more importantly, the therapy gets closer to patients."
At the Pivot of Industry Innovation
At the heart of industry innovation, WuXi AppTec anchors every breakthrough in quality, drives it with speed, and supports it with an integrated, end-to-end platform.
"The value of the CRDMO model goes beyond individual licensing deals," Dr. Yang emphasized. "Its deeper significance lies in accelerating complex therapies that would otherwise take years to reach patients, turning scientific potential into tangible impact."
As science pushes boundaries, WuXi AppTec stands as a key node in the global “flat world,” linking ideas, expertise, and resources to accelerate breakthroughs from lab to life.
It is more than a service provider—it is a bridge. Through its end-to-end platform, combining quality and speed, WuXi AppTec connects small biotech scientific insights, large pharma strategic planning, investor confidence, and regulatory rigor. Isolated ideas cross resource, capability, and geographic gaps, accelerating their path to patients.
In today’s vibrant landscape of global innovation, the value of this bridge has never been more tangible.
版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。
分享，点赞，在看，聚焦全球生物医药健康创新